BioCentury
ARTICLE | Company News

Trianta, Helmholtz Zentrum Muenchen, Max Delbrueck Center for Molecular Medicine Berlin-Buch deal

January 20, 2014 8:00 AM UTC

The Max Delbrueck Center and Helmholtz Zentrum Muenchen granted newco Trianta exclusive, worldwide rights to IP and know-how related to technologies to develop personalized dendritic cell vaccines and adoptive T cell therapies. Under the deal, Ascenion GmbH, the technology transfer partner to the Max Delbrueck Center and Helmholtz Zentrum Muenchen, acquired an undisclosed equity stake in Trianta. Helmholtz Zentrum Muenchen spun off Trianta in late 2013. ...